Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President's Budget Proposal Points To Expanding FDA User Fees

This article was originally published in The Tan Sheet

Executive Summary

President Obama's fiscal 2012 budget request concurs with FDA in recommending that Congress expand the type of user fees that industry pays for food safety enforcement reform.

You may also be interested in...



FDA White Oak Construction Nears Completion, But Some Plans On Hold

The biodefense complex would remain on schedule for fiscal 2014 completion, but communications and logistical buildings included in the master plan would be on hold. FDA tells Congress the sprawling campus must receive necessary operational funds as more employees move there.

FDA White Oak Construction Nears Completion, But Some Plans On Hold

The biodefense complex would remain on schedule for fiscal 2014 completion, but communications and logistical buildings included in the master plan would be on hold. FDA tells Congress the sprawling campus must receive necessary operational funds as more employees move there.

FDA Proposes Expanding User Fees To Cosmetics Among New Areas

The White House requests a 17% increase in FDA’s overall budget to $4.5 billion, including $855 million in direct appropriations for CFSAN, about $10 million less than its fiscal 2012 appropriation, and $473 million for CDER, about $5 million less than its current appropriation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel